Clinical Quality Registry for Cervical Cancer
Funding body
MRFF
Years currently funded
2024 – 2028
Background
In 2020 the World Health Organization (WHO) released a global strategy to accelerate the elimination of cervical cancer (CC) as a public health problem within the next 100 years. Three years later, Australia released its National Strategy for the Elimination of Cervical Cancer (CC) in Australia. This strategy promises to make Australia the first country to achieve the elimination of CC by equitably providing high coverage, high quality prevention and care across the three pillars of vaccination, screening and treatment.
Critically, the pillar which currently has the least data to inform this action plan is the treatment pillar, with no national data able to determine current rates of treatment, let alone quality of care for those diagnosed with CC.
Leveraging the existing infrastructure of the National Gynae-Oncology Registry (NGOR), the Clinical Quality Registry for Cervical Cancer is an important, cost- and time-efficient step to closing that knowledge gap.
Stakeholders
The project has been developed with registry personnel, clinicians, and key stakeholder groups across cancer care, policy, and consumers including the Australian Centre for the Prevention of Cervical Cancer, the Daffodil Centre, and Cancer Council.
Data
The registry integrates standard quantitative registry datapoints and health information, with the addition of patient-reported outcomes and experiences, along with data from the National Cancer Screening Register (cervical screening history), the Australian Immunisation Register (HPV vaccination), the National Death Index (survival data), and hospital administrative datasets to create a unified, national Cervical Cancer Data Asset.
Benefits
The registry harnesses existing NGOR infrastructure and relationships, making it a cost- and time-efficient way to create the Cervical Cancer Data Asset and share findings. Analysis of the data will help Australia benchmark its progress to meeting the goal of elimination by 2035, and identify priority audiences based on geographic and demographic factors to guide creation of awareness campaigns and programs to increase uptake of screening and vaccination where needed.
Contact
Dr Sharnel Perera
Program Manager, National Gynae-Oncology Registry
T: +61 3 9903 9257
E: Sharnel.Perera@monash.edu
Twitter: @NGOR_Aus